Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer

Although FOLFIRINOX (l-Leucovorin/5-FU/Irinotecan/Oxaliplatin) is established as one of the standard therapies for patients with metastatic pancreatic cancer, the modified FOLFIRINOX (mFOLFIRINOX) is often used in clinical practice to reduce the incidence of toxicities. Febrile neutropenia (FN) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Irisawa, Ai, Takeno, Misaki, Watanabe, Kazuo, Takahashi, Hideaki, Mitsunaga, Shuichi, Ikeda, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481868/
https://www.ncbi.nlm.nih.gov/pubmed/36114233
http://dx.doi.org/10.1038/s41598-022-18669-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481868/
https://www.ncbi.nlm.nih.gov/pubmed/36114233
http://dx.doi.org/10.1038/s41598-022-18669-9

Ejemplares similares